Osteoporosis management in post-menopausal women.
Level 5 - mechanism / opinion, no new human data
Narrative review of guidelines and selected literature without systematic review methodology
What was done
The authors conducted a narrative literature search in PubMed for articles published between 2007 and 2012 (filtering for English language, human studies, females aged 45+, review articles, and free full text) along with the 2010 North American Menopause Society (NAMS) position statement and hand-searched references to summarize osteoporosis management and pharmacological therapies in postmenopausal women.
What was found
The abstract reports the following comparative fracture risk reductions from reviewed literature: - Bisphosphonates (first-line): reduce vertebral fractures by 40% to 70% and non-vertebral fractures by 20% to 35%. - Denosumab: reduces vertebral fractures by 68% and non-vertebral fractures by 19%. - Teriparatide (severe osteoporosis): reduces vertebral fractures by 65% and non-vertebral fractures by 53%. - Selective estrogen receptor modulators (SERMs, e.g., raloxifene, bazedoxifene): reduce vertebral fractures by 55% with no documented benefit for non-vertebral fractures. - Estrogen: associated with a 27% reduction in fractures. - Calcitonin: 33% fracture reduction reported in early 2000 trials, but findings were unreplicated (relegated to second-line). - Calcium and vitamin D supplementation: trials reported mixed findings on effectiveness.
Why it matters
It provides a consolidated summary of fracture reduction magnitudes across major postmenopausal osteoporosis drug classes relative to the 2010 NAMS guidelines to inform clinical decision-making.
Limits
The review relies on highly restrictive search filters (limited to free full-text reviews), introducing significant selection bias. No systematic screening, meta-analytic pooling, confidence intervals, or quality grading of individual trials are provided, and total participant counts are not reported.
Cited by
- supports Bisphosphonates are considered first-line pharmacological therapy for osteoporosis.